Table 3: Results of the main clinical trials

Study

Population

Treatment

Baseline IOP

Follow-up

IOP reduction

Definition success

Response rate

Nagar et al50

167 patients with OHTN or OAG newly diagnosed or medically controlled after 8 washout

Xalatan

29.3

Mean 10.3 months (range 1-12)

NA

IOP reduction $ 20% IOP reduction $ 30% with no additional medications

90% 78%

IOP reduction $ 20%

90°SLT

IOP reduction $ 30% with no additional medications

34% 11%

SLT IOP reduction $ 20%

180°SLT

IOP reduction $ 30% with no additional medications

65%

IOP reduction $ 20%

48%

IOP reduction $ 30% with no additional medications

82%

360°SLT

59%

Mcllraith et al52

100 eyes with newly diagnosed early OAG and OHTN

Latanoprost (26 eyes)

24.6

12 months

7.7 mm Hg (30.6%)

IOP reduction $ 30%

43%

SLT inferior 180° SLT (74 eyes)

26.0

8.3 mm Hg (31%)

IOP reduction $ 30%

55%

Lai et al51

29 Chinese patients with POAG or OHTN, newly diagnosed

360 SLT (fellow eye treated with medication)

26.2-4.2

5 years (82.8% completed)

8.6-6.7 mm Hg (32.1%)

IOP #21 mm Hg without medication IOP #21 mm Hg on MTMT

72% 83%

Jay Katz et al49

69 patients (127 eyes OAG or OHTN were randomized to SLT or medical therapy

SLT (100 applications 360°) or medical therapy (prostaglandin analog)

24.5 mm Hg 24.7 mm Hg in the medical group

9 to 12 months

(6.3 mm Hg reduction) in the SLT arm, (7.0 mm Hg reduction) in the medical arm